Clinical Trial Update: Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Completed Phase 1/2 safety study evaluating MKC-1 in combination with pemetrexed for advanced cancer and non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• MKC-1
• Pemetrexed (pemetrexed)

Snippet

Sponsor: CASI Pharmaceuticals, Inc. | Conditions: Advanced Cancer, Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED